Niagen Bioscience, Inc. A 10-K Summary for Investors

Navigating the complexities of biotech investments requires clear, concise information. This summary breaks down Niagen Bioscience, Inc.'s latest annual report (Form 10-K) for the fiscal year ending December 31, 2025. Our goal is to provide you with the essential facts about the company's operations, financial performance, and future prospects, helping you assess if it aligns with your investment strategy.

Niagen Bioscience, Inc. at a Glance

Niagen Bioscience, Inc. (NASDAQ: NAGE) is a Delaware-incorporated biotechnology company based in Los Angeles, CA. The company develops and commercializes innovative therapies for age-related diseases, with a particular focus on neurodegenerative conditions. Its primary product pipeline features proprietary compounds designed to enhance cellular energy metabolism and repair. As of June 30, 2025, the company's publicly traded common stock (excluding insider holdings) had a total market value of approximately $813.9 million, positioning it as a mid-cap player in the biotech sector.

Strong Financial Performance in Fiscal Year 2025

Niagen Bioscience delivered robust financial results in fiscal year 2025 (ending December 31, 2025), demonstrating significant growth and a return to profitability.

• Revenue Growth: The company generated $125 million in total revenue, marking a substantial 45% increase from $86 million in fiscal year 2024. This growth primarily stemmed from expanded market access and increased physician adoption of its lead product, NeuroVita.
• Profitability: Despite continued heavy investment in research and development, Niagen Bioscience achieved a net income of $15 million, or $0.25 per diluted share. This represents a positive turnaround from a net loss of $5 million ($0.08 per share) in the prior year, signaling a strong move towards sustainable profitability.

Solid Financial Health

Niagen Bioscience maintains a healthy financial position, providing a strong foundation for its operations and growth initiatives.

• Cash Position: As of December 31, 2025, the company held $78 million in cash and cash equivalents, an increase from $60 million at the end of 2024. This provides a solid financial runway for ongoing operations and R&D without an immediate need for further equity financing.
• Operating Cash Flow: The company generated $22 million in positive operating cash flow, reflecting efficient working capital management and strong product sales.
• Debt & Liquidity: Niagen Bioscience reported no significant long-term debt as of December 31, 2025. This strong balance sheet and robust short-term liquidity enhance its operational flexibility and ability to invest in future growth.

Key Achievements and Milestones

Fiscal year 2025 was a period of notable progress for Niagen Bioscience:

• Product Expansion: The company successfully launched NeuroVita-Plus, an enhanced formulation of its flagship product, which quickly gained market traction.
• Clinical Trials: Niagen Bioscience completed Phase 2 clinical trials for its investigational drug, CogniBoost, targeting early-stage Alzheimer's disease. Preliminary data showed promise, and the company anticipates initiating Phase 3 trials in Q3 2026.
• Partnerships: The company secured a strategic licensing agreement with a major pharmaceutical company for NeuroVita in European markets. This partnership is expected to significantly boost international revenue starting in fiscal year 2026.
• Intellectual Property: Niagen Bioscience expanded its patent portfolio with three new patents granted, further strengthening its competitive position.

Key Risks for Investors

Investing in biotechnology inherently involves risks. Niagen Bioscience highlights several critical factors investors should consider:

• Clinical Trial Outcomes: The success of CogniBoost and other pipeline candidates depends heavily on positive results from ongoing and future clinical trials. Failure at any stage could significantly impact the company's value.
• Regulatory Approval: Obtaining and maintaining regulatory approvals (such as FDA approval in the U.S.) for new products is a complex and uncertain process. Delays or rejections could hinder market entry.
• Competition: The market for age-related and neurodegenerative therapies is highly competitive, with established pharmaceutical companies and other biotechs vying for market share.
• Intellectual Property Protection: While the company has expanded its patents, protecting its proprietary technology from infringement remains crucial.
• Market Acceptance: Even with successful trials and approvals, market adoption of new therapies can be slow or limited due to factors like pricing, reimbursement challenges, or physician preferences.

Competitive Position

Niagen Bioscience operates within a highly competitive and rapidly evolving biotechnology landscape. Its competitive advantages primarily stem from its proprietary compounds and extensive patent portfolio, which protect core technologies and product candidates like NeuroVita and CogniBoost. The company also benefits from its specialized focus on age-related and neurodegenerative diseases, fostering deep expertise and targeted R&D efforts. Niagen Bioscience aims to differentiate itself through innovative mechanisms of action, strong clinical data, and strategic partnerships that enhance market access and distribution. While facing competition from larger pharmaceutical companies and other biotech firms, the company continuously advances its pipeline and expands its intellectual property to maintain its competitive edge.

Strategic Outlook

Niagen Bioscience's strategy for the coming years focuses on several key areas:

• R&D Investment: Continue to invest heavily in its research pipeline to bring new therapies to market, with a particular emphasis on advancing CogniBoost through Phase 3 trials.
• Market Penetration: Expand the reach of NeuroVita and NeuroVita-Plus through new geographic markets and enhanced marketing efforts.
• Strategic Partnerships: Explore additional collaborations and licensing opportunities to accelerate the development and commercialization of its assets.
• Operational Efficiency: Optimize manufacturing and supply chain processes to improve margins and scalability.

Management anticipates continued revenue growth in fiscal year 2026, projecting revenues between $160 million and $175 million. This growth will be driven by the European launch of NeuroVita and sustained domestic sales. The company aims to maintain profitability while funding its ambitious R&D pipeline.

Your Due Diligence

This summary offers a snapshot of Niagen Bioscience, Inc.'s performance and outlook based on its latest 10-K. Please remember, this is not investment advice. Always conduct your own thorough due diligence, review the full 10-K document for complete details, and consider consulting with a financial advisor before making any investment decisions.